Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER TEENS
2023-506923-27-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Oral semaglutide plus background therapy with Placebo plus background therapy (2 arms). Primary endpoint: Change from baseline to week 26 in HbA1c. Started Jun 2024; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-506923-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506923-27-00.